The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study

समान संसाधन

• The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma
  द्वारा: Ping-Chih Hsu, और अन्य
  प्रकाशित: (2020-02-01)
• The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma
  द्वारा: Hsu, Ping-Chih, और अन्य
  प्रकाशित: (2020)
• Baseline and changes in inflammatory parameters for patients with EGFR‐mutated NSCLC treated with afatinib
  द्वारा: Zi‐Ting Chang, और अन्य
  प्रकाशित: (2025-07-01)
• Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study
  द्वारा: Wu, Chiao-En, और अन्य
  प्रकाशित: (2021)
• Impact of prolonged and early bevacizumab treatment on the overall survival of EGFR‐mutant and EGFR‐wild type nonsquamous non‐small cell lung cancer
  द्वारा: Huang, Yu‐Chen, और अन्य
  प्रकाशित: (2018)